
Precision Timing: Finding the 'Goldilocks' Zone for Prostate Cancer Therapy
A massive analysis of over 10,000 patients reveals that the benefits of hormone therapy for prostate cancer generally plateau after one year. While the treatment effectively suppresses tumours, extending it too long increases the risk of death from other causes, suggesting shorter, personalised durations are often safer.
By Zaorsky, Sun, Nabid, Zapatero, Bolla, Joseph, Maingon, Guerrero, Gonzalez, San-Segundo, Cabeza Rodríguez, Sole, Olivé, Steigler, Souhami, Carrier, Armstrong, Gillham, Pisansky, Schipper, Sandler, Efstathiou, Lawton, de Reijke, Attard, Roy, Morgan, Malone, Hall, Nguyen, Shoag, Vince, Calaway, Garcia, Barata, Mendiratta, Brown, Valle, Rettig, Dess, Jackson, Martin, Jia, Steinberg, Romero, Kishan, Spratt

